Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib and Necitumumab in EGFR-Mutant NSCLC
NCT02496663Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of necitumumab and osimertinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 21 days and Incidence of toxicity up to 1 year. Started May 2016; status: active, not recruiting.
02
Drugs
necitumumabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02496663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496663.